-
-
VOLUNTARY ANNOUNCEMENTVOLUNTARY ANNOUNCEMENT PRE-APPLICATION FOR CLINICAL TRIALS FOR ABSORBED TETANUS VACCINE SUBMITTED
2024-03-05The board of directors of the Company (the “Board”) is pleased to announce that the pre-application for clinical trials for the Group’s absorbed tetanus vaccine has been submitted recently. The research and development of the vaccine is in line with the Company’s strategic layout in product research and development and is an important step to realize the Company’s research and development of multidisease and multivalent products, which will further improve the Company’s product pipelines, help the Company consolidate its industry position in the field of vaccines not covered by the immunization programs (Class II vaccine) in China, and contribute to the sustainable development of the Company’s vaccine business.
-
-
VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE II CLINICAL TRIAL OF TETRAVALENT MENINGOCOCCAL CONJUGATE VACCINE
2024-03-05The board of directors of the Company (the “Board”) is pleased to announce that on March 2, 2024, the randomized, blinded and comparable vaccine-controlled Phase II clinical trial of the Group’s tetravalent meningococcal conjugate vaccine (MCV4) was officially initiated, with the Yunnan Provincial Center for Disease Control and Prevention as the responsible institution, and the Center for Disease Control and Prevention of Longyang District, Baoshan and the Center for Disease Control and Prevention of Weishan Yi and Hui Autonomous County, Dali Prefecture as the research sites.
-
-
AIM Vaccine Rises on its First Day on HKEx Main Board
2022-10-12 -
AIM Vaccine Co., Ltd. (06660.HK) closed at HK$ 16.66, up 3.09%, on October 6, its first day on HKEx Main Board.
-
-
-
Phase II Clinical Data on AIM’s mRNA Impressive and Significantly Effective On Omicron
2022-08-24 -
The data from the phase II clinical trial of mRNA (LVRNA009) targeting Covid-19 - independently developed by AIM Vaccine, have been known to the public. The live virus-neutralizing antibodies tested by Wuhan Institute of Virology, CAS, revealed that, the geometric mean titer (GMT) of the live virus-neutralizing antibodies 14 days after full-course vaccination of mRNA, was 994.9 in the adult medium-dose group and 1405.7 in the adult high-dose group. These figures prove mRNA is fairly strong in immunogenicity. Of note, the independent third-party tests indicate mRNA (LVRNA009) could fend off Omicron variants to a great extent.
-
-
-
Upgrade for Higher Safety ▏AIM Rong’an Submitted Clinical Application for Serum-free Human Rabies Vaccine to CDE
2021-12-15 -
Rong’an Bio, a wholly-owned subsidiary of AIM Vaccine, has submitted its application of communication session for the freeze-dried rabies vaccine for human use (serum-free Vero cell) it developed to the Center for Drug Evaluation (CDE), NMPA, thus entering the communication stage. As an upgrade, the serum-free Vero cell human rabies vaccine is most prominently characterized by serum-free cell culture, which results in higher safety.
-
-
-
Hardcore Technology ▏AIM Convac Submitted Clinical Application for EV71-CA16 HFMD Vaccine (HDC) to CDE
2021-12-09 -
A few days ago, AIM Convac, a subsidiary of AIM Vaccine Co., Ltd, submitted its application of communication session for the EV71-CA16 bivalent HFMD vaccine (human diploid cell) it developed to the Center for Drug Evaluation (CDE), NMPA, thus entering the communication stage. This candidate vaccine can target the two most common pathogens causing the hand-foot-and-mouth disease, i.e., enteric virus type 71 (EV71) and Coxsackie virus group A type 16 (CA16), to play an immunoprotective role in the comprehensive control and prevention of an HFMD epidemic.
-
-
-
Rising Star of International First-line Vaccine ▏AIM Vaccine MCV4 Obtained Clinical Approval
2021-12-01 -
Another success of AIM Vaccine Co., Ltd.—its wholly-owned subsidiary AIM Vacin obtained the Notice of Approval for Drug Clinical Trial for its ACYW135 Meningococcus Conjugate Vaccine (MCV4) from the National Medical Products Administration on December 1, and will carry out clinical trials in accordance with the requirements in the Notice.MCV4 is an industry-recognized international first-line innovative vaccine, and so far no similar product of its kind has obtained approval in China.
-
-
-
R&D of vaccine targeted at COVID-19 Delta variant has been incorporated into “Pioneer Program” of Zhejiang Province for rolling submission to CDE.
2021-11-27 -
As declared by Zhejiang Provincial Department of Science and Technology on November 26, 2021, R&D of COVID-19 Vaccine Targeted at Delta Variant has been incorporated into Key “Pioneer” R&D Projects of Zhejiang Province for the year of 2022. This project is initiated by Ningbo Rong’an Biological Pharmaceutical Co., Ltd through cooperation with Zhejiang Provincial Center for Disease Control and Prevention. As the collaborator, Ningbo Rong’an Biological Pharmaceutical Co., Ltd is accelerating the development of inactivated COVID-19 vaccine targeted at Delta variant. So far, it has entered the non-clinical animal evaluation stage, including animal safety evaluation, immunogenicity evaluation and protection evaluation. In the near future, it will proceed with rolling submission of relevant information to Center for Drug Evaluation (CDE), NMPA.
-
